Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardant Health, Inc. (Nasdaq: GH), a precision oncology company based in Palo Alto, California. Through these filings, investors and analysts can review the company’s official disclosures about its capital structure, governance, and key events related to its blood and tissue tests, real-world data activities, and AI analytics in cancer care.
Guardant Health’s common stock is registered on The Nasdaq Global Select Market under the symbol GH, as noted in its Form 8-K filings. The company files current reports on Form 8-K to describe material events, such as public offerings of common stock, private offerings of convertible senior notes, results of stockholder meetings, financial results announcements, and board appointments. These documents outline details like underwriting agreements, convertible note terms, and voting outcomes at annual meetings.
In addition to Form 8-K reports, Guardant Health files annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain more extensive information about its business, risk factors, and financial statements. Proxy statements on Schedule 14A provide further detail on governance matters and executive compensation. Together, these filings offer a regulatory record of how the company finances its operations, manages its corporate governance, and communicates significant developments to the market.
On Stock Titan, Guardant Health’s SEC filings are updated as they are made available through the EDGAR system. AI-powered tools can help summarize long documents, highlight key terms in offerings and note indentures, and make it easier to locate information on topics such as capital raises, voting results, and reporting obligations. This page is intended as a convenient starting point for reviewing Guardant Health’s regulatory disclosures in one place.
Guardant Health, Inc. director reports RSU vesting and share acquisition. On 12/17/2025, reporting person Manuel Hidalgo Medina acquired 232 shares of Guardant Health common stock at a price of $0 through the settlement of previously granted restricted stock units, reported with transaction code M.
The restricted stock units were granted on July 17, 2024 and vest over four years, with 25% of the shares vesting on the one-year anniversary of that date and the remaining 75% vesting monthly over the following three years. After this transaction, the reporting person beneficially owns 1,029 shares of common stock directly and 7,193 restricted stock units.
Guardant Health, Inc. director Musa Tariq disclosed a small sale of company stock. On 12/17/2025, the reporting person sold 116 shares of Guardant Health common stock at a price of $101.46 per share. After this transaction, the director beneficially owned 7,993 shares of Guardant Health common stock, held in direct ownership. This filing is a routine insider ownership update and does not describe any additional transactions or derivative securities.
Guardant Health, Inc. director reports routine vesting of restricted stock units. On 12/15/2025, a reporting person who serves as a director of Guardant Health, Inc. (ticker GH) acquired 250 shares of common stock at a price of $0 through the vesting and settlement of previously granted restricted stock units. After this transaction, the director beneficially owned 8,109 shares of common stock directly and 3,748 restricted stock units that remain outstanding.
The restricted stock units were originally granted on March 6, 2023 and vest over four years. According to the vesting schedule, 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting in equal monthly installments over the following three-year period.
Guardant Health, Inc. reported insider equity activity by its Chief Legal Officer, John G. Saia. On 12/15/2025, 1,020 restricted stock units were converted to common stock at an exercise price of $0, increasing his directly held common shares to 44,192 before related tax actions. On the same date, 535 common shares were withheld and disposed of at $102.67 per share to satisfy tax withholding obligations tied to the vesting of the restricted stock units, leaving him with 43,657 common shares held directly.
The derivative securities table shows that these transactions relate to a restricted stock unit award granted on June 9, 2023, covering common stock. After the reported conversion of 1,020 units, Saia continues to hold 2,039 restricted stock units, which vest over a three-year period, with 33% having vested on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.
Guardant Health, Inc. (GH) disclosed an insider equity transaction by its Chief Information Officer, Kumud Kalia. On 12/15/2025, 637 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of restricted stock units. On the same date, 323 shares were disposed of at $102.67 per share, with the company retaining these shares to satisfy tax withholding obligations related to the vesting. After these transactions, the reporting person beneficially owned 22,679 shares of common stock directly, along with 1,275 restricted stock units that remain outstanding and subject to future vesting.
Guardant Health, Inc. reported an insider stock transaction by its Chief Commercial Officer. On December 15, 2025, the officer acquired 1,402 shares of common stock at $0 when a portion of a restricted stock unit (RSU) award vested. On the same date, 594 shares were withheld and disposed of at $102.67 per share to cover tax withholding obligations, as explained in the footnotes.
After these transactions, the officer directly owned 26,795 shares of Guardant Health common stock. The RSU award was originally granted on June 9, 2023; 33% vested on June 15, 2024, and the remaining 67% is scheduled to vest in equal quarterly installments over the following two years. Following the reported transaction, 2,804 restricted stock units remained beneficially owned.
Guardant Health, Inc. Co-Chief Executive Officer and director Helmy Eltoukhy reported open-market sales of company stock. On 12/15/2025, he sold 83,945 shares of common stock at a weighted average price of
Guardant Health, Inc. reported an insider equity transaction by its Chief Medical Officer, Craig Eagle. On 12/15/2025, 1,402 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of previously granted restricted stock units. On the same date, 711 shares were disposed of at $102.67 per share, retained by the company to cover tax withholding obligations related to this vesting.
Following these transactions, Craig Eagle beneficially owned 45,007 shares of Guardant Health common stock directly, and held 2,804 restricted stock units as derivative securities. The underlying restricted stock unit award was granted on June 9, 2023 and vests over a three-year period, with 33% having vested on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.
Guardant Health, Inc. (GH) Chief Technology Officer Darya Chudova sold 5,451 shares of common stock on 12/15/2025 at a weighted average price of $104.0418 per share. The sale was executed through multiple transactions at prices ranging from $104.0401 to $104.0900. Following this transaction, Chudova beneficially owns 7,012 shares of Guardant Health common stock in direct ownership.
Guardant Health, Inc.'s Chief Financial Officer, Michael Brian Bell, reported equity transactions involving restricted stock units and common stock. On 12/15/2025, 1,233 and 2,039 restricted stock units were converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held common shares. On the same date, 1,659 shares of common stock were withheld and disposed of at $102.67 per share to satisfy tax withholding obligations related to the vesting, with the filing stating that the amount retained was not in excess of the tax liability. After these transactions, he directly beneficially owned 29,665 shares of common stock and held 4,078 restricted stock units that continue to vest over multi‑year schedules.